Business Profile

Description: Nurix, Inc. is a science-focused and goal-oriented organization that is committed to bringing novel, first-in-class therapies to patients. Nurix is a leader in discovering a new class of drugs that work by modulating the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein stabilization and degradation UO a function vital to the healthy life of a cell UO offering therapeutic opportunities in multiple disease areas. The Nurix scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the UPS, enabling the development of new class of drugs that can restore normal cellular homeostasis. Nurix was founded by internationally-recognized experts in the UPS field and received its initial funding from leading life science investors, Third Rock Ventures and The Column Group. The Company recently entered into a multi-year strategic collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix is based in San Francisco, California. For further information please visit our website: www.nurix-inc.com